Long-term data boosts transmyocardial laser revascularisation (TMR) approval hopes
This article was originally published in Clinica
Executive Summary
Eclipse Surgical has presented the FDA with what it says are favourable 12-month follow-up data from its trials of transmyocardial laser revascularisation technology.